Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines

Vaccine

Volumn 29, Issue 8, 2011, Pages 1666-1676

  Green, Sharone ^a   Ennis, Francis A ^a   Mathew, Anuja ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Aging; CD8; Vaccinia

Indexed keywords

CD27 ANTIGEN; EPITOPE; MODIFIED VACCINIA ANKARA VACCINE; NEW YORK CITY BOARD OF HEALTH VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROVOCATION TEST; SPLEEN; VACCINATION; VACCINIA VIRUS; VIRUS DETECTION;

EID: 79952699569     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.036     Document Type: Article

References (46)

1. Fenner F. Smallpox: emergence, global spread, and eradication. History and Philosophy of the Life Sciences 1993;15(3):397-420.
2. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005;23(March (17-18)):2078-81.
3. Artenstein AW. New generation smallpox vaccines: a review of preclinical and clinical data. Reviews in Medical Virology 2008;18(July-August (4)):217-31.
4. Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and feasibility. Expert Review of Vaccines 2008;7(October (8)):1225-37.
5. Sugimoto M, Yasuda A, Miki K, Morita M, Suzuki K, Uchida N, et al. Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains. Microbiology and Immunology 1985;29(5):421-8.
6. Mayr A, Munz E. Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene 1 Abt Medizinischhygienische Bakteriologie, Virusforschung und Parasitologie Originale 1964;195:24-35.
7. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Deutsche medizinische Wochenschrift 1974;99(November (47)):2386-92.
8. Tartaglia J,Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188(May (1)):217-32.
9. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG. The non-replicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005;341(October (1)):91-101.
10. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immuno-genicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004;428(March (6979)):182-5.
11. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proceedings of the National Academy of Sciences of the United States of America 2008;105(August (31)):10889-94.
12. Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidatesin mice and comparison with the traditional 1st generation vaccine. Vaccine 2008;26(March (14)):1794-804.
13. McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clinical Infectious Diseases 2004;38(June (12)):1749-53.
14. Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 2005;339(September (2)):164-75.
15. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. Journal of Virology 2005;79(June (12)):7845-51.
16. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24(March (12)):2065-70.
17. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, et al. Vaccinia virus vaccines: past, present and future. Antiviral Research 2009;84(October (1)):1-13.
18. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. The Journal of General Virology 1991;72(May (Pt 5)):1031-8.
19. Abdalrhman I, Gurt I, Katz E. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA). Vaccine 2006;24(May (19)):4152-60.
20. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, et al. Safety,immunogenicity and efficacy of modified vaccinia Ankara(MVA)against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007;25(February (8)):1513-25.
21. Meyer VS, Kastenmuller W, Gasteiger G, Franz-Wachtel M, Lamkemeyer T, Rammensee HG, et al. Long-term immunity against actual poxviral HLA lig-ands as identified by differential stable isotope labeling. Journal of Immunology 2008;181(November (9)):6371-83.
22. Demkowicz Jr WE, Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. Journal of Virology 1996;70(April (4)):2627-31.
23. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nature Medicine 2003;9(September (9)):1131-7.
24. Kapasi ZF, Murali-Krishna K, McRae ML, Ahmed R. Defective generation but normal maintenance of memory T cells in old mice. European Journal of Immunology 2002;32(June (6)):1567-73.
25. Hikono H, Kohlmeier JE, Ely KH, Scott I, Roberts AD, Blackman MA, et al. T-cell memory and recall responses to respiratory virus infections. Immunological Reviews 2006;211(June):119-32.
26. + T cells. The Journal of Experimental Medicine 2007;204(July (7)):1625-36.
27. Mathew A, O'Bryan J, Marshall W, Kotwal GJ, Terajima M, Green S, et al. Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus. PloS One 2008;3(10):e3323.
28. + T cell determinants to enable rational design and characterization of smallpox vaccines. The Journal of Experimental Medicine 2005;201(January (1)):95-104.
29. + CTL epitopes with distinct functional profiles. Journal of Immunology 2005;174(February (4)):2212-9.
30. Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proceedings of the National Academy of Sciences of the United States of America 2004;101(March (13)):4590-5.
31. Chandele A, Joshi NS, Zhu J, Paul WE, Leonard WJ, Kaech SM. Formation of IL-7Ralphahigh and IL-7Ralphalow CD8 T cells during infection is regulated by the opposing functions of GABPalpha and Gfi-1. Journal of Immunology 2008;180(April (8)):5309-19.
32. Blaser C, Kaufmann M, Pircher H. Virus-activated CD8 T cells and lymphokine-activated NK cells express the mast cell function-associated antigen, an inhibitory C-type lectin. Journal of Immunology 1998;161(December (12)):6451-4.
33. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and genomic profilingofeffectorCD8Tcell subsets with distinct memory fates. The Journal of Experimental Medicine 2008;205(March (3)):625-40.
34. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007;27(August (2)):281-95.
35. + T cells expressing the inhibitory killer cell lectin-like receptor G1(KLRG1). Experimental Gerontology 2003;38(August (8)):911-20.
36. Kohlmeier JE, Woodland DL. Immunity to respiratory viruses. Annual Review of Immunology 2009;27:61-82.
37. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007;25(February (10)):1814-23.
38. Jentarra GM, Heck MC, Youn JW, Kibler K, Langland JO, Baskin CR, et al. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine 2008;26(June (23)):2860-72.
39. Smee DF, Bailey KW, Sidwell RW. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chemistry & Chemotherapy 2001;12(January (1)):71-6.
40. + T-cell peptide epitope of vaccinia and variola viruses. Journal of Virology 2004;78(July (13)):7052-60.
41. + T-cell epitopes in the murine intranasal challenge model. European Journal of Immunology 2009;39(March (3)):717-22.
42. Cornberg M,Sheridan BS, Saccoccio FM, Brehm MA, Selin LK. Protection against vacciniavirus challenge by CD8 memory T cells resolved by molecular mimicry. Journal of Virology 2007;81(January (2)):934-44.
43. Joshi NS, Kaech SM. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. Journal of Immunology 2008;180(February (3)):1309-15.
44. + memory T cells and their capacity for secondary expansion. Journal of Immunology 2005;175(August (3)):1665-76.
45. - T cells. European Journal of Immunology 2005;35(November (11)):3131-41.
46. Peperzak V, Xiao Y, Veraar EA, Borst J. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. The Journal of Clinical Investigation 2010;120:168-78, doi:10.1172/JCI40178.